Top

Published in:

01-10-2015

Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion and positron emission tomography/computed tomography of upper gastrointestinal cancers

Authors: Minoru Tomizawa, Fuminobu Shinozaki, Yoshitaka Uchida, Katsuhiro Uchiyama, Kazunori Fugo, Takafumi Sunaoshi, Aika Ozaki, Eriko Sugiyama, Akira Baba, Yoshiya Fukamizu, Satoshi Kagayama, Rumiko Hasegawa, Yoshinori Shirai, Yuji Oshima, Naoto Koike, Yasuko Toshimitsu, Yasufumi Motoyoshi, Takao Sugiyama, Shigenori Yamamoto, Takashi Kishimoto, Naoki Ishige

Published in: Abdominal Radiology | Issue 8/2015

Abstract

Purpose

Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion (DWIBS/T2) strongly contrasts cancerous tissue against background healthy tissues. Positron emission tomography/computed tomography (PET/CT) applies the uptake of 18-fluorodeoxyglucose in the diagnosis of cancer. Our aim was to compare DWIBS/T2 and PET/CT in patients with upper gastrointestinal cancers.

Methods

Patient records, including imaging results from July 2012 to March 2015, were analyzed retrospectively. Four men (age, 72.5 ± 5.3 years) and ten women (age, 71.6 ± 4.0 years) were enrolled in this study. The numbers of patients with esophageal cancer, gastric cancer, gastrointestinal stromal tumor, and duodenal cancer were one, eight, three, and two, respectively.

Results

Six out of eight patients with gastric cancer had positive results on both DWIBS/T2 and PET/CT. The diameter and depth of invasion of gastric cancer was larger in patients with positive DWIBS/T2 and PET/CT findings than those with negative findings. These results suggested that patients with gastric cancer with larger pixel numbers might tend to show positive results with DWIBS/T2.

Conclusions

DWIBS/T2 and PET/CT have similar sensitivity for the diagnosis of upper gastrointestinal cancer. The diameter and depth of invasion affected the detectability of gastric cancer.

Allum WH, Blazeby JM, Griffin SM, et al. (2011) Guidelines for the management of oesophageal and gastric cancer. Gut 60(11):1449–1472. doi:10.1136/gut.2010.228254 CrossRefPubMed

Labianca R, Nordlinger B, Beretta GD, et al. (2013) Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi64–vi72. doi:10.1093/annonc/mdt354 CrossRefPubMed

Jurgensen C, Brand J, Nothnagel M, et al. (2013) Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc 27(4):1124–1129. doi:10.1007/s00464-012-2558-z CrossRefPubMed

Dai T, Popa E, Shah MA (2014) The role of (1)(8)F-FDG PET imaging in upper gastrointestinal malignancies. Curr Treat Options Oncol 15(3):351–364. doi:10.1007/s11864-014-0301-9 CrossRefPubMed

Kato H, Kuwano H, Nakajima M, et al. (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94(4):921–928. doi:10.1002/cncr.10330 CrossRefPubMed

Komori T, Narabayashi I, Matsumura K, et al. (2007) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 21(4):209–215. doi:10.1007/s12149-007-0010-6 CrossRefPubMed

Takahara T, Imai Y, Yamashita T, et al. (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22(4):275–282PubMed

Sehy JV, Ackerman JJ, Neil JJ (2002) Apparent diffusion of water, ions, and small molecules in the Xenopus oocyte is consistent with Brownian displacement. Magn Reson Med 48(1):42–51. doi:10.1002/mrm.10181 CrossRefPubMed

Koike N, Cho A, Nasu K, et al. (2009) Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions. World J Gastroenterol 15(46):5805–5812PubMedCentralCrossRefPubMed

10.

Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18(9):1937–1952. doi:10.1007/s00330-008-0968-z PubMedCentralCrossRefPubMed

11.

Ohno Y, Koyama H, Onishi Y, et al. (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248(2):643–654. doi:10.1148/radiol.2482072039 CrossRefPubMed

12.

Fischer MA, Nanz D, Hany T, et al. (2011) Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET/CT. Eur Radiol 21(2):246–255. doi:10.1007/s00330-010-1929-x CrossRefPubMed

13.

Sommer G, Wiese M, Winter L, et al. (2012) Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol 22(12):2859–2867. doi:10.1007/s00330-012-2542-y CrossRefPubMed

14.

Nechifor-Boila IA, Bancu S, Buruian M, et al. (2013) Diffusion weighted imaging with background body signal suppression/T2 image fusion in magnetic resonance mammography for breast cancer diagnosis. Chirurgia (Bucur) 108(2):199–205

15.

Rutkowski P, Wozniak A, Debiec-Rychter M, et al. (2011) Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer 117(21):4916–4924. doi:10.1002/cncr.26079 CrossRefPubMed

16.

Wang Y, Miller FH, Chen ZE, et al. (2011) Diffusion-weighted MR imaging of solid and cystic lesions of the pancreas. Radiographics 31(3):E47–E64. doi:10.1148/rg.313105174 CrossRefPubMed

17.

Tanaka S, Ikeda K, Uchiyama K, et al. (2013) [18F]FDG uptake in proximal muscles assessed by PET/CT reflects both global and local muscular inflammation and provides useful information in the management of patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 52(7):1271–1278. doi:10.1093/rheumatology/ket112 CrossRef

18.

Grabinska K, Pelak M, Wydmanski J, Tukiendorf A, d’Amico A (2015) Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol 21(19):5901–5909. doi:10.3748/wjg.v21.i19.5901 PubMedCentralPubMed

19.

Shinya S, Sasaki T, Nakagawa Y, et al. (2007) The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology 54(77):1378–1381PubMed

20.

Liu S, He J, Guan W, et al. (2014) Preoperative T staging of gastric cancer: comparison of diffusion- and T2-weighted magnetic resonance imaging. J Comput Assist Tomogr 38(4):544–550. doi:10.1097/RCT.0000000000000090 CrossRefPubMed

21.

Liu S, He J, Guan W, et al. (2014) Added value of diffusion-weighted MR imaging to T2-weighted and dynamic contrast-enhanced MR imaging in T staging of gastric cancer. Clin Imaging 38(2):122–128. doi:10.1016/j.clinimag.2013.12.001 CrossRefPubMed

22.

Caivano R, Rabasco P, Lotumolo A, et al. (2014) Gastric cancer: The role of diffusion weighted imaging in the preoperative staging. Cancer Invest 32(5):184–190. doi:10.3109/07357907.2014.896014 CrossRefPubMed

23.

Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M (2006) Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 20(9):597–604CrossRefPubMed

24.

Yun M (2014) Imaging of gastric cancer metabolism using 18 F-FDG PET/CT. J Gastric Cancer 14(1):1–6. doi:10.5230/jgc.2014.14.1.1 PubMedCentralCrossRefPubMed

25.

Cayvarli H, Bekis R, Akman T, Altun D (2014) The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence. Mol Imaging Radionucl Ther 23(3):76–83. doi:10.4274/mirt.83803 PubMedCentralCrossRefPubMed

26.

Ulusan S, Koc Z (2009) Radiologic findings in malignant gastrointestinal stromal tumors. Diagn Interv Radiol 15(2):121–126PubMed

27.

Wong CS, Gong N, Chu YC, et al. (2012) Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV. Eur J Radiol 81(9):2122–2126. doi:10.1016/j.ejrad.2011.09.003 CrossRefPubMed

28.

Yu MH, Lee JM, Baek JH, Han JK, Choi BI (2014) MRI features of gastrointestinal stromal tumors. AJR Am J Roentgenol 203(5):980–991. doi:10.2214/AJR.13.11667 CrossRefPubMed

29.

Schmidt S, Dunet V, Koehli M, et al. (2013) Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT. Acta Radiol 54(8):837–842. doi:10.1177/0284185113485732 CrossRefPubMed

30.

Tomizawa M, Shinozaki F, Hasegawa R, et al. (2015) Factors affecting the detection of colorectal cancer and colon polyps on screening abdominal ultrasonography. Hepatogastroenterology 62(138):295–298PubMed

Title: Diffusion-weighted whole-body imaging with background body signal suppression/T2 image fusion and positron emission tomography/computed tomography of upper gastrointestinal cancers
Authors: Minoru Tomizawa
Fuminobu Shinozaki
Yoshitaka Uchida
Katsuhiro Uchiyama
Kazunori Fugo
Takafumi Sunaoshi
Aika Ozaki
Eriko Sugiyama
Akira Baba
Yoshiya Fukamizu
Satoshi Kagayama
Rumiko Hasegawa
Yoshinori Shirai
Yuji Oshima
Naoto Koike
Yasuko Toshimitsu
Yasufumi Motoyoshi
Takao Sugiyama
Shigenori Yamamoto
Takashi Kishimoto
Naoki Ishige
Publication date: 01-10-2015
Publisher: Springer US
Published in: Abdominal Radiology / Issue 8/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-015-0545-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2015

CT prediction of the Fuhrman grade of clear cell renal cell carcinoma (RCC): towards the development of computer-assisted diagnostic method

Role of imaging for patients with colorectal hepatic metastases: what the radiologist needs to know

Use of a web-based image reporting and tracking system for assessing abdominal imaging examination quality issues in a single practice

Revisiting the potential signs of colorectal cancer on contrast-enhanced computed tomography without bowel preparation

Erratum to: Hot spleen: hypervascular lesions of the spleen

A structured approach to reporting rectal cancer with magnetic resonance imaging

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials